1. Clinical Overview
Tolvaptan is a selective, competitive vasopressin V2-receptor antagonist (aquaretic agent) that promotes free water excretion (aquaresis) without significant electrolyte loss. It is used to treat hyponatremia (low blood sodium) associated with conditions like SIADH, heart failure, and cirrhosis, and to slow kidney function decline in adult patients with autosomal dominant polycystic kidney disease (ADPKD).
| Onset | Duration | Bioavailability |
|---|---|---|
| 2 to 4 hours after oral administration. | Approximately 24 hours. | Approximately 40-56%. |
2. Mechanism of Action
Tolvaptan competitively blocks vasopressin from binding to V2 receptors in the renal collecting ducts. This inhibition prevents the insertion of aquaporin-2 water channels into the luminal membrane, reducing water reabsorption. The result is an increase in free water excretion (aquaresis) and a decrease in urine osmolality, leading to a net increase in serum sodium concentration.
3. Indications & Uses
- Treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and resistant to fluid restriction)
- To slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
4. Dosage & Administration
Adult Dosage: Hyponatremia: Initiate with 15 mg once daily. May increase to 30 mg once daily after at least 24 hours, and to a maximum of 60 mg once daily based on serum sodium levels. ADPKD: Initiate with 45 mg (AM dose) + 15 mg (PM dose) for first week, then titrate to 60 mg + 30 mg, and then to 90 mg + 30 mg if tolerated. Doses should be split (morning and afternoon).
Administration: Take orally with or without food. For hyponatremia, initiate in-hospital. For ADPKD, take the first dose upon waking and the second dose 8-9 hours later. Avoid grapefruit juice. Ensure adequate fluid intake to avoid dehydration.
5. Side Effects
Common side effects may include:
- Thirst (polydipsia)
- Dry mouth
- Polyuria (increased urination)
- Nocturia
- Fatigue
- Constipation
- Hyperglycemia
- Hyperuricemia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ketoconazole, Itraconazole, Clarithromycin, Ritonavir | Significantly increases tolvaptan exposure. Contraindicated. | High |
| Moderate CYP3A4 Inhibitors (e.g., Erythromycin, Fluconazole, Verapamil, Diltiazem) | Increases tolvaptan exposure. Use with caution and reduce tolvaptan dose. | Moderate |
| CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin, St. John's Wort) | Decreases tolvaptan exposure. May require dose adjustment. | Moderate |
| Hypertonic Saline | Increased risk of overly rapid correction of serum sodium. Avoid concomitant use. | High |
| Diuretics (especially loop diuretics) | May increase risk of dehydration and electrolyte imbalance. Monitor closely. | Moderate |
| ACE Inhibitors, ARBs, NSAIDs, Potassium-sparing diuretics | May increase risk of hyperkalemia. Monitor potassium levels. | Moderate |
| Digoxin | Tolvaptan may increase digoxin levels. Monitor digoxin levels. | Moderate |
| Desmopressin | May blunt the aquaretic effect of tolvaptan. | Moderate |
7. Patient Counselling
- DO take the medication exactly as prescribed, at the recommended times (especially for ADPKD split dosing).
- DO ensure you have access to water to drink in response to thirst.
- DO report any signs of liver problems (yellowing of skin/eyes, dark urine, fatigue, abdominal pain) immediately.
- DO inform all your doctors and pharmacists that you are taking tolvaptan.
- DONT drink grapefruit juice or eat grapefruit.
- DONT take the medication if you are unable to drink fluids or feel thirsty.
- DONT start or stop any other medication without consulting your doctor.
8. Toxicology & Storage
Overdose: Expected consequences would arise from its pharmacologic effect: profound aquaresis leading to severe dehydration, hypernatremia, hypovolemia, hypotension, circulatory collapse, and acute renal failure. Symptoms include extreme thirst, dry mucous membranes, dizziness, weakness, tachycardia, and oliguria.
Storage: Store at room temperature (15°C to 30°C). Protect from moisture. Keep in the original blister pack or container. Keep out of reach of children.